MA43529A - Modulateurs de transport nucléaire et leurs utilisations - Google Patents
Modulateurs de transport nucléaire et leurs utilisationsInfo
- Publication number
- MA43529A MA43529A MA043529A MA43529A MA43529A MA 43529 A MA43529 A MA 43529A MA 043529 A MA043529 A MA 043529A MA 43529 A MA43529 A MA 43529A MA 43529 A MA43529 A MA 43529A
- Authority
- MA
- Morocco
- Prior art keywords
- nuclear transport
- transport modulators
- modulators
- nuclear
- transport
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562273857P | 2015-12-31 | 2015-12-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA43529A true MA43529A (fr) | 2018-11-07 |
Family
ID=57799957
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA043529A MA43529A (fr) | 2015-12-31 | 2016-12-30 | Modulateurs de transport nucléaire et leurs utilisations |
Country Status (4)
Country | Link |
---|---|
US (1) | US10526295B2 (fr) |
EP (1) | EP3397633A1 (fr) |
MA (1) | MA43529A (fr) |
WO (1) | WO2017117529A1 (fr) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20210083380A (ko) | 2011-07-29 | 2021-07-06 | 카리오팜 쎄라퓨틱스, 인코포레이티드 | 하이드라지드 함유 핵 수송 조절인자 및 이의 용도 |
IN2014DN09434A (fr) | 2012-05-09 | 2015-07-17 | Karyopharm Therapeutics Inc | |
US10202366B2 (en) | 2013-03-15 | 2019-02-12 | Karyopharm Therapeutics Inc. | Methods of promoting wound healing using CRM1 inhibitors |
ES2952774T3 (es) | 2013-06-21 | 2023-11-06 | Karyopharm Therapeutics Inc | 1,2,4-triazoles como moduladores del transporte nuclear y uso en el tratamiento de formas específicas de cáncer |
JP6777626B2 (ja) | 2014-08-15 | 2020-10-28 | カリオファーム セラピューティクス,インコーポレイテッド | セリネクソールの多形体 |
US10526295B2 (en) | 2015-12-31 | 2020-01-07 | Karyopharm Therapeutics Inc. | Nuclear transport modulators and uses thereof |
MA43530A (fr) | 2015-12-31 | 2018-11-07 | Karyopharm Therapeutics Inc | Modulateurs de transport nucléaire et leurs utilisations |
US11602530B2 (en) | 2016-11-28 | 2023-03-14 | Biogen Ma Inc. | CRM1 inhibitors for treating epilepsy |
RU2756512C1 (ru) | 2018-01-10 | 2021-10-01 | ЭксДабл-ЮФАРМА ЛТД. | Пролекарства кетамина, его композиции и применения |
WO2019232724A1 (fr) * | 2018-06-06 | 2019-12-12 | Xw Laboratories, Inc. | Composés en tant que modulateurs de transport nucléaire et leurs utilisations |
WO2021247447A1 (fr) * | 2020-06-01 | 2021-12-09 | Luke Klele | Compositions antivirales |
WO2022089629A1 (fr) * | 2020-11-02 | 2022-05-05 | 江苏柯菲平医药股份有限公司 | Dérivé de 1,2,4-triazole, son procédé de préparation et son utilisation |
CA3219525A1 (fr) * | 2021-05-20 | 2022-11-24 | Erkan Baloglu | Procedes de synthese de derives heteroaryles de triazolyl acrylamides et de formes cristallines |
US11690811B2 (en) | 2021-08-13 | 2023-07-04 | XWPharma Ltd. | Pharmaceutical compositions and oral dosage forms of ketamine derivatives |
WO2023036217A1 (fr) * | 2021-09-08 | 2023-03-16 | 南京明德新药研发有限公司 | Composé d'acrylamide et son utilisation |
WO2023072248A1 (fr) * | 2021-10-29 | 2023-05-04 | 正大天晴药业集团股份有限公司 | Composé contenant du pyridyle |
WO2023134629A1 (fr) * | 2022-01-12 | 2023-07-20 | 上海海雁医药科技有限公司 | Régulateur de transport nucléaire et son utilisation |
Family Cites Families (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1017398A (en) | 1911-01-16 | 1912-02-13 | John E Folsom | Telegraph-key. |
KR840000529A (ko) | 1981-07-07 | 1984-02-25 | 콘스탄틴 루이스 클레멘트 | 인돌 유도체의 제조방법 |
CS229934B2 (en) | 1981-07-07 | 1984-07-16 | Pfizer | Production method subst.indolylacryte acid derivative |
US4778796A (en) | 1985-07-19 | 1988-10-18 | Dainippon Pharmaceutical Co., Ltd. | ω-(3-pyridyl)alkenamide derivatives and anti-allergenic pharmaceutical compositions containing same |
IL97249A (en) | 1990-02-23 | 1995-01-24 | Takeda Chemical Industries Ltd | Compounds of 7,6,5,4-tetrahydrothiazole] B-5,4 [pyridine and compounds of 5,6-dihydro-H4-pyrrolo] D-3,2 [thiazole, their manufacture, and pharmaceutical compositions including or |
JP3111321B2 (ja) | 1990-02-23 | 2000-11-20 | 武田薬品工業株式会社 | 縮合チアゾール化合物 |
US5541213A (en) | 1993-06-24 | 1996-07-30 | Eisai Co., Ltd. | Propenoic acid derivatives diazole propenoic acid compounds which have useful pharmaceutical utility |
EP0793653A1 (fr) | 1994-11-23 | 1997-09-10 | Neurogen Corporation | Certains derives 4-aminomethyl 2-substitues de l'imidazole et derives 2-aminomethyl 4-substitues de l'imidazole, nouvelles categories de ligands specifiques du sous-type du recepteur de la dopamine |
US20030018025A1 (en) | 1995-06-07 | 2003-01-23 | Neurogen Corporation, Corporation Of The State Of Delaware | Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives: new classes of dopamine receptor subtype specific ligands |
EP0858457A1 (fr) | 1995-10-20 | 1998-08-19 | Dr. Karl Thomae GmbH | Heterocycles a 5 chainons, medicaments contenant ces composes, utilisation et procede de production correspondants |
ATE341554T1 (de) | 1996-04-04 | 2006-10-15 | Shionogi & Co | Cephemverbindungen und medikamente die diese verbindungen enthalten |
TW449460B (en) | 1996-04-25 | 2001-08-11 | Nissan Chemical Ind Ltd | Ethylene derivatives and pest controlling agents |
JP4054992B2 (ja) | 1996-04-25 | 2008-03-05 | 日産化学工業株式会社 | エチレン誘導体および有害生物防除剤 |
DE19624659A1 (de) | 1996-06-20 | 1998-01-08 | Klinge Co Chem Pharm Fab | Neue Pyridylalken- und Pyridylalkinsäureamide |
US5994398A (en) | 1996-12-11 | 1999-11-30 | Elan Pharmaceuticals, Inc. | Arylsulfonamides as phospholipase A2 inhibitors |
JP4416198B2 (ja) | 1997-12-19 | 2010-02-17 | 武田薬品工業株式会社 | アニリド誘導体、その製造法および用途 |
WO1999050264A1 (fr) | 1998-03-30 | 1999-10-07 | Kyowa Hakko Kogyo Co., Ltd. | Derives de quinazoline |
AR029803A1 (es) | 2000-02-21 | 2003-07-16 | Smithkline Beecham Plc | Imidazoles sustituidos con piridilo y composiciones farmaceuticas que las comprenden |
EP2083005A1 (fr) | 2000-09-29 | 2009-07-29 | TopoTarget UK Limited | Composés d'acide carbamique comportant une liaison d'amide en tant qu'inhibiteurs HDAC |
CN101851173A (zh) | 2001-09-14 | 2010-10-06 | 梅特希尔基因公司 | 组蛋白脱乙酰化酶抑制剂 |
AU2003287965A1 (en) | 2002-10-24 | 2004-05-13 | Carex Sa | Modulation of peroxisome proliferator activated receptors activity |
DE10250743A1 (de) | 2002-10-31 | 2004-05-19 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Amid-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel |
JP4145230B2 (ja) | 2002-11-01 | 2008-09-03 | 武田薬品工業株式会社 | 神経障害の予防・治療剤 |
NZ540381A (en) | 2002-11-01 | 2007-11-30 | Takeda Pharmaceutical | 5-membered aromatic heterocycle derivatives as prophylactic and therapeutic agents for treating neuropathy |
CA2504941C (fr) | 2002-11-08 | 2012-06-26 | Neurogen Corporation | 6-arylpyridines substituees en position 3 |
WO2004076418A1 (fr) | 2003-02-28 | 2004-09-10 | Galderma Research & Development, S.N.C. | Ligands modulant des recepteurs du type lxr |
TWI335816B (en) | 2004-05-26 | 2011-01-11 | Eisai R&D Man Co Ltd | Cinnamide compound |
BRPI0515015A (pt) | 2004-08-11 | 2008-07-01 | Kyorin Seiyaku Kk | derivado cìclico de ácido aminobenzóico; medicamento; agonista ppar(alpha); agonista duplo ppar(alpha), y; agonista duplo ppar(alpha), (delta); modulador ppar; agente lipìdeo; agente profilático ou terapêutico compreendendo pelo menos um dos derivados cìclicos de ácido aminobenzóico ou sal do mesmo farmacêuticamente aceitável |
WO2006019020A1 (fr) | 2004-08-16 | 2006-02-23 | Sankyo Company, Limited | Urées de substitution |
EP1849465A4 (fr) | 2005-02-18 | 2008-12-24 | Takeda Pharmaceutical | Agent de controle de la fonction du recepteur gpr34 |
US8637559B2 (en) | 2005-11-15 | 2014-01-28 | Otsuka Pharmaceutical Co., Ltd. | Oxazole compound and pharmaceutical composition |
JP2007210929A (ja) | 2006-02-09 | 2007-08-23 | Sankyo Co Ltd | ウレア化合物を含有する医薬 |
EA016464B1 (ru) | 2006-03-09 | 2012-05-30 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Полициклические производные арилимидазола |
WO2007118137A1 (fr) | 2006-04-07 | 2007-10-18 | Methylgene Inc. | Dérivés de benzamide utilisés en tant qu'inhibiteurs de l'histone désacétylase |
SI2014652T1 (sl) | 2006-04-18 | 2014-12-31 | Nippon Chemiphar Co., Ltd. | Aktivacijsko sredstvo za peroksisomski proliferatorski aktivirani receptor |
US8653115B2 (en) | 2006-06-13 | 2014-02-18 | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | Heterocyclic non-nucleoside compounds, their preparation, pharmaceutical composition and their use as antiviral agents |
WO2008013414A1 (fr) | 2006-07-27 | 2008-01-31 | Amorepacific Corporation | Nouveaux composés, isomères de ceux-ci, ou sels acceptables sur le plan pharmaceutique de ceux-ci utilisés en tant qu'antagonistes du récepteur vanilloïde, et compositions pharmaceutiques les contenant |
ES2376668T3 (es) | 2006-09-05 | 2012-03-15 | Kyowa Hakko Kirin Co., Ltd. | Derivado de imidazol. |
EP1942104A1 (fr) | 2006-12-20 | 2008-07-09 | sanofi-aventis | Hétéroarylcyclopropanecarboxamide et leur utilisation pharmaceutique |
EP1939180A1 (fr) | 2006-12-20 | 2008-07-02 | sanofi-aventis | Hétéroarylacrylamides et leur utilisation en tant que médicament pour la stimulation de l'expression de la synthase NO endotheliale |
US7795457B2 (en) | 2007-02-26 | 2010-09-14 | Kosan Biosciences Incorporated | Carbamate compounds |
EP2003118A1 (fr) | 2007-06-13 | 2008-12-17 | Bayer Schering Pharma Aktiengesellschaft | Dérivés d'acides de cannelle en tant que modulateurs du récepteur EP2 |
CA2767661A1 (fr) | 2009-07-09 | 2011-01-13 | Crescendo Therapeutics, Llc | Procede de guerison de lesion et de modulation de cicatrice |
US8518968B2 (en) | 2009-12-04 | 2013-08-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Hydrazone and diacyl hydrazine compounds and methods of use |
CN103002742B (zh) | 2010-03-05 | 2016-07-13 | 卡尔约药物治疗公司 | 核转运调节剂及其应用 |
AU2012207565B2 (en) | 2011-01-17 | 2016-04-07 | Karyopharm Therapeutics Inc. | Olefin containing nuclear transport modulators and uses thereof |
US9428490B2 (en) | 2011-07-29 | 2016-08-30 | Karyopharm Therapeutics Inc. | Nuclear transport modulators and uses thereof |
KR20210083380A (ko) | 2011-07-29 | 2021-07-06 | 카리오팜 쎄라퓨틱스, 인코포레이티드 | 하이드라지드 함유 핵 수송 조절인자 및 이의 용도 |
WO2013020024A2 (fr) | 2011-08-03 | 2013-02-07 | Karyopharm Therapeutics, Inc. | Composés de maléimide et méthodes de traitement |
IN2014DN09434A (fr) | 2012-05-09 | 2015-07-17 | Karyopharm Therapeutics Inc | |
CN102777158B (zh) | 2012-07-06 | 2014-09-10 | 西南石油大学 | 测调联动系统及其操作工艺 |
WO2014152263A1 (fr) | 2013-03-15 | 2014-09-25 | Karyopharm Therapeutics Inc. | Modulateurs de transport nucléaire contenant une exo-oléfine et leurs utilisations |
US10202366B2 (en) | 2013-03-15 | 2019-02-12 | Karyopharm Therapeutics Inc. | Methods of promoting wound healing using CRM1 inhibitors |
WO2014205393A1 (fr) | 2013-06-21 | 2014-12-24 | Karyopharm Therapeutics Inc. | Modulateurs de transport nucléaire et leurs utilisations |
ES2952774T3 (es) | 2013-06-21 | 2023-11-06 | Karyopharm Therapeutics Inc | 1,2,4-triazoles como moduladores del transporte nuclear y uso en el tratamiento de formas específicas de cáncer |
WO2015073908A1 (fr) | 2013-11-15 | 2015-05-21 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Procédé de sélection d'un schéma de traitement du cancer |
US9828373B2 (en) | 2014-07-26 | 2017-11-28 | Sunshine Lake Pharma Co., Ltd. | 2-amino-pyrido[2,3-D]pyrimidin-7(8H)-one derivatives as CDK inhibitors and uses thereof |
JP6777626B2 (ja) | 2014-08-15 | 2020-10-28 | カリオファーム セラピューティクス,インコーポレイテッド | セリネクソールの多形体 |
MA43530A (fr) | 2015-12-31 | 2018-11-07 | Karyopharm Therapeutics Inc | Modulateurs de transport nucléaire et leurs utilisations |
US10526295B2 (en) | 2015-12-31 | 2020-01-07 | Karyopharm Therapeutics Inc. | Nuclear transport modulators and uses thereof |
US11602530B2 (en) | 2016-11-28 | 2023-03-14 | Biogen Ma Inc. | CRM1 inhibitors for treating epilepsy |
-
2016
- 2016-12-30 US US16/066,554 patent/US10526295B2/en active Active
- 2016-12-30 WO PCT/US2016/069492 patent/WO2017117529A1/fr active Application Filing
- 2016-12-30 MA MA043529A patent/MA43529A/fr unknown
- 2016-12-30 EP EP16826682.3A patent/EP3397633A1/fr not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
US10526295B2 (en) | 2020-01-07 |
EP3397633A1 (fr) | 2018-11-07 |
WO2017117529A1 (fr) | 2017-07-06 |
US20190016690A1 (en) | 2019-01-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA43529A (fr) | Modulateurs de transport nucléaire et leurs utilisations | |
MA50618A (fr) | Polyrhérapies et leurs utilisations | |
MA49537A (fr) | Anticorps anti-lag3 et leurs utilisations | |
MA46708A (fr) | Anticorps anti-pd1 et leurs utilisations | |
FIC20230014I1 (fi) | Foslevodopa ja foskarbidopa | |
MA42622A (fr) | Agents de liaison à tigit et leurs utilisations | |
MA56480A (fr) | Agonistes du récepteur glp-1 et leurs utilisations | |
MA50502A (fr) | Adénovirus et utilisations associées | |
MA53145A (fr) | Agents de liaison cd123 et leurs utilisations | |
MA43530A (fr) | Modulateurs de transport nucléaire et leurs utilisations | |
MA45235A (fr) | Anticorps anti-c5 et leurs utilisations | |
MA53400A (fr) | Hétéromultimères alk7: actriib et leurs utilisations | |
MA50256A (fr) | Composés de pyrazolopyrimidinone et leurs utilisations | |
MA42935A (fr) | Anticorps bispécifiques anti-cd3 optimisés et leurs utilisations | |
MA47789A (fr) | Anticorps anti-phf-tau et leurs utilisations | |
MA45125A (fr) | Anticorps anti-alpha-synucléine et leurs utilisations | |
MA53184A (fr) | Anticorps anti-ox40 et leurs utilisations | |
MA41460A (fr) | Agents de liaison à la tnfrsf et leurs utilisations | |
MA43567A (fr) | Anticorps pacap et leurs utilisations | |
MA43205A (fr) | Composés pyy sélectifs et leurs utilisations | |
DK3308111T3 (da) | Belastningsføler og belastningsføler-anlæg | |
MA43821A (fr) | Pyrimidines et variantes de celles-ci, et leurs utilisations | |
DK3177259T3 (da) | Forbindelses- og beholdersystem | |
MA41919A (fr) | Hétéromultimères alk4:actriib et leurs utilisations | |
MA44262A (fr) | Bioconjugués et utilisations de ceux-ci |